RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
1. RYBREVANT® and LAZCLUZE® show significant resistance reduction in NSCLC treatments. 2. Overall survival is projected to exceed four years with the new combination. 3. Resistance rates for tumors treated with RYBREVANT® plus LAZCLUZE® are significantly lower. 4. Combination therapy may open future treatment options and prolong patient survival. 5. Safety profile of combined treatments remains consistent, with no new safety signals.